Equities

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Actions
  • Price (EUR)15.90
  • Today's Change-4.50 / -22.06%
  • Shares traded700.00
  • 1 Year change+17.78%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments578484447
Total Receivables, Net1.234.060.43
Total Inventory------
Prepaid expenses2.001.140.64
Other current assets, total0.060.190.50
Total current assets581490448
Property, plant & equipment, net1.501.061.26
Goodwill, net------
Intangibles, net------
Long term investments305.47--
Note receivable - long term------
Other long term assets0.460.810
Total assets613497450
LIABILITIES
Accounts payable9.964.355.67
Accrued expenses412515
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.010.010
Other current liabilities, total7.2300.19
Total current liabilities582921
Total long term debt0.010.0120
Total debt0.020.0220
Deferred income tax------
Minority interest------
Other liabilities, total0.580.710.71
Total liabilities593041
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,4561,161952
Retained earnings (accumulated deficit)(902)(693)(544)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.22(0.81)0.05
Total equity554467408
Total liabilities & shareholders' equity613497450
Total common shares outstanding856855
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.